Resistance to antibiotics in Pseudomonas aeruginosa;Rezistencija na antibiotike u Pseudomonas aeruginosa

Infektoloski Glasnik

Volumn 29, Issue 4, 2009, Pages 177-183

  Sardelić, Sanda ^a   Bedenić, Branka ^b  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Efflux; Pseudomonas aeruginosa; Resistance; lactamases

Indexed keywords

BETA LACTAM ANTIBIOTIC;

ANTIBIOTIC RESISTANCE; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 77951132627     PISSN: 13312820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Hurst V, Sutter V. Survival of Pseudomonas aeruginosa in the hospital environment. J Infect Dis 1966; 116: 151-154.
2. National Nosocomial Infection Surveillance System. National nosocomial infections surveillance (NNIS) report, data summary from October 1986-April 1996, issued may 1996. Am J Infect Control 1996; 24: 380-388.
3. Stover CK, Pham XQ, Erwin AL, i sur. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406(6799): 959-964.
4. Woodruff WA, Hancock RE. Construction and characterization of Pseudomonas aeruginosa protein F-deficient mutants after in vitro and in vivo insertion mutagenesis of the cloned gene. J Bacteriol 1988; 170: 2592-2598.
5. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-250.
6. Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999; 43: 1085-1090 (Pubitemid 29214729)
7. Schweizer HP. Efflux as mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res 2003; 2: 48-62.
8. Poole K. Multidrug efflux pumps and antimicrobial reistance in Pseudomonas aeruginosa and related organism. J Mol Microbiol Biotechnol 2001; 3: 255-264.
9. Ziha-Zarifi I, Llanes C, Köhler T, Pechere JC, Plesiat P. In vivo emergence of multidrug resistant mutants of Pseudomonas aeruginosa overexpressing active efflux system MexA-MexB-OprmM. Antimicrob Agents Chemother 1997; 43: 287-291.
10. Livermore DM. Radiolabeling of penicillin-binding proteins (PBPs) in intact Pseudomonas aeruginosa cells: consequences od β-lactamase activity by PBP-5. J Antimicrob Chemother 1987; 19: 733-742.
11. Bellido F, Veuthey C, Blaser J, i sur. Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. J Antimicrob Chemother 2001; 45: 480-484.
12. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
13. Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occuring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48(6): 2043-2048 (Pubitemid 38691595)
14. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends in Microbiol 2006; 14(9): 413-420.
15. Livermore D. Clinical significanse of β-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987; 19: 439-445 (Pubitemid 18074757)
16. Livermore DM. Multiple mechanisms of resistance in Pseudomonas aeruginosa, our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
17. Shanon KP, King A, Philips I. Development of resistance to β-lactam antibiotics during therapy of Pseudomonas aeruginosa infections. Lancet 1982;i:1466. (Pubitemid 12123992)
18. Pechere JC, Kohler T. Patterns and models of β-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5(supl. 1): S15-8. (Pubitemid 29141346)
19. Chen HY, Yuan M, Livermore D. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995;43:300-309.
20. Sanschagrin F, Bejaoui N, Levasque RC. Structure of CARB-4 and AER-1 carbenicillin hydrolyzing β-lactamases. Antimicrob Agents Chemother 1998; 42(8): 1966-1972 (Pubitemid 28363077)
21. st century: characterisation, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14(4): 933-951.
22. Giske CG, Sundsfjord AS, Kahlmeter G, i sur. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J Antimicrob Chemother 2009; 63(1): 1-4.
23. Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 2002; 50: 11-18 (Pubitemid 34785249)
24. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999; 5: 865-879.
25. Philippon LN, Naas T, Bouthors AT, Barakett V, Nordmann P. OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2188-2195 (Pubitemid 27422211)
26. Gupta V. Metallo-β-lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opinion Investig Drugs 2008; 17(2): 131-143 (Pubitemid 351578196)
27. Livermore DM, Woodford N. Carbapenemase: a problem waiting? Curr Opin Microbiol 2000; 3: 489-495.
28. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-325.
29. Yong D, Bell JM, Ritchie B, Pratt R, Toleman MA, Walsh TR. A novel sub-group metallo-β-lactamase (MBL), AIM-1, emerges in Pseudomonas aeruginosa (PSA) from Australia. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007. abstr. C1-593.
30. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35(1): 147-151.
31. Senda K, Arakawa Y, Ichiyama S, i sur. PCR detection of metallo-β-lactamase gene (blaIMP) in gram-negative rods resistant to broad spectrum β-lactams. J Clin Microbiol 1996; 34(12): 2909-2913.
32. Pellegrini C, Mercuri PS, Celenza G, i sur. Identification of bla(IMP-22) in Pseudomonas spp. in urban wastewater and nosocomial environments: biochemical characterization of a new IMP metallo-enzyme variant and its genetic location. J Antimicrob Chemother 2009; 63(5): 901-908.
33. Lauretti L, Riccio ML, Mazzariol A, i sur. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999; 43(7): 1584-1590.
34. Poirel L, Lambert T, Turkoglu S, Ronco E, Gaillard J, Nordmann P. Characterization of class 1 integrons from Pseudomonas aeruginosa that contain the blaVIM-2 carbapenem hydrolyzing β-lactamase gene and two novel aminoglycosides resistance gene cassettes. Antimicrob Agents Chemother 2001; 45(2): 546-552 (Pubitemid 32106716)
35. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 2009; 58: 1133-1148.
36. Sardelic S, Pallecchi L, Punda Polic V, Rossolini GM. Carbapenem-resistant Pseudomonas aeruginosa carrying VIM-2 metallo-β- lactamase determinants, Croatia. Emerg Infect Dis 2003; 9: 1022-1023.
37. Bedenic B, Mazzariol A, Jarza-Davila N, Plecko V, Cornaglia G, Fontana R. VIM-2 metallo-β-lactamase in Pseudomonas aeruginosa strains from Zagreb, Croatia. Clin Microbiol Infect 2006;12(Suppl 4):P928. (Abstracts from the 16th European Congress of Clinical Microbiology and Infectious Disease, Nice, France April 1-4, 2006).
38. Lepsanovic Z, Libisch B, Tomanovic B, Nonkovici Z, Balogh B, Füzi M. Characterisation of the first VIM metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolate in Serbia. Acta Microbiol Immunol Hung 2008; 55(4):447-454.
39. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-β-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). Antimicrob Agents Chemother 2009; 53: 1225-1227.
40. MacLeod DL, Nelson LE, Shawar RM, i sur. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. Infect Dis 2000; 181(3): 1180-1184.
41. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44(12): 3322-3327
42. Vakulenko SB, Mobashery S. Versality of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003; 16: 430-450 (Pubitemid 36871315)
43. Doi Y, de Oliveira Garcia D, Adams J, Paterson DL. Coproduction of novel 16S rRNA methylase RmtD and metallo-β-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother 2007; 51(3): 852-856 (Pubitemid 46355266)
44. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337-341.
45. Li XZ, Barré N, Poole K. Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 46(6): 885-893 (Pubitemid 32000597)
46. Kohler T, Michea-Hamzehpour M, Pesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux system by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2540-2543. (Pubitemid 27467570)
47. Tambić Andrašević A, Tambić T. Rezistencija bakterijskih izolata u 2008. godini. U: Tambić T, Tambić Andrašević A, ur. Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2008. godini. Zagreb: Akademija medicinskih znanosti Hrvatske, 2009: 9-98.